Source:http://linkedlifedata.com/resource/pubmed/id/16625522
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2006-4-25
|
| pubmed:abstractText |
Adjustment Disorders With Anxiety (ADWA) account for almost 10% of psychologically motivated consultations in primary care. The aim of this double-blind randomised parallel group study was to compare (non-inferiority test) the efficacies of etifoxine, a non-benzodiazepine anxiolytic drug, and lorazepam, a benzodiazepine, for ADWA outpatients followed by general practitioners. 191 outpatients (mean age: 43, female: 66%) were assigned to receive etifoxine (50 mg tid) or lorazepam (0.5-0.5-1 mg /day) for 28 days. Efficacy was evaluated on days 7 and 28 of the treatment. The main efficacy assessment criterion was the Hamilton Rating Scale for Anxiety score (HAM-A) on Day 28 adjusted to Day 0. The anxiolytic effect of etifoxine was found not inferior to that of lorazepam (HAM-A score decrease: 54.6% vs 52.3%, respectively, p=0.0006). The two drugs were equivalent on Day 28. However, more etifoxine recipients responded to the treatment (HAM-A score decreased by >or=50%, p=0.03). Clinical improvement (based on Clinical Global Impression scale CGI, Social Adjustment Scale Self-Report SAS-SR, and Sheehan scores) was observed in both treatment arms, but more etifoxine patients improved markedly (p=0.03) and had a marked therapeutic effect without side effects as assessed by CGI, p=0.04. Moreover, 1 week after stopping treatment, fewer patients taking etifoxine experienced a rebound of anxiety, compared to lorazepam (1 and 8, respectively, p=0.034).
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0885-6222
|
| pubmed:author | |
| pubmed:copyrightInfo |
Copyright (c) 2006 John Wiley & Sons, Ltd.
|
| pubmed:issnType |
Print
|
| pubmed:volume |
21
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
139-49
|
| pubmed:dateRevised |
2009-10-27
|
| pubmed:meshHeading |
pubmed-meshheading:16625522-Adjustment Disorders,
pubmed-meshheading:16625522-Adolescent,
pubmed-meshheading:16625522-Adult,
pubmed-meshheading:16625522-Aged,
pubmed-meshheading:16625522-Anti-Anxiety Agents,
pubmed-meshheading:16625522-Anxiety,
pubmed-meshheading:16625522-Confidence Intervals,
pubmed-meshheading:16625522-Dose-Response Relationship, Drug,
pubmed-meshheading:16625522-Double-Blind Method,
pubmed-meshheading:16625522-Drug Evaluation,
pubmed-meshheading:16625522-Family Practice,
pubmed-meshheading:16625522-Female,
pubmed-meshheading:16625522-Humans,
pubmed-meshheading:16625522-Lorazepam,
pubmed-meshheading:16625522-Male,
pubmed-meshheading:16625522-Middle Aged,
pubmed-meshheading:16625522-Oxazines,
pubmed-meshheading:16625522-Prospective Studies,
pubmed-meshheading:16625522-Retrospective Studies,
pubmed-meshheading:16625522-Severity of Illness Index,
pubmed-meshheading:16625522-Time Factors
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice.
|
| pubmed:affiliation |
CPCET et Pharmacologie Clinique, Institut des Neurosciences Cognitives de la Méditerranée, Faculté de Médecine, UMR CNRS Université de la Méditerranée, Assistance Publique Hôpitaux de Marseille-Hôpital de la Timone, 13385 Marseille Cedex 5, France.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|